TY - CHAP
T1 - COPD and Other Inflammatory Diseases of the Lung
T2 - Focus on AhR Signaling
AU - Beamer, Celine A.
AU - Seaver, Benjamin P.
AU - Shepherd, David M.
N1 - Publisher Copyright:
© 2012, Springer Science+Business Media, LLC.
PY - 2012
Y1 - 2012
N2 - Millions of individuals worldwide are afflicted with disorders affecting the lungs, resulting in difficulty breathing. Oftentimes, these diseases occur as a result of altered immune response in the lung. The aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor, acts as a regulator of mucosal barrier function and may influence immune responsiveness in lung diseases through changes in gene expression, cell-cell adhesion, mucin production, and cytokine expression. Of these cytokines, interleukin 22 (IL-22) signaling appears to be involved in lung inflammation and fibrosis, and both endogenous and exogenous AhR agonists promote IL-22 expression. Therefore, this chapter discusses the role of the AhR pathway and IL-22 signaling in lung diseases such as chronic obstructive pulmonary disorder, idiopathic fibrosis, Sarcoidosis, acute respiratory distress syndrome, and silicosis. Finally, we address the therapeutic potential of targeting the AhR—IL-22 axis in regulating immunity, inflammation, and tissue homeostasis in lung diseases.
AB - Millions of individuals worldwide are afflicted with disorders affecting the lungs, resulting in difficulty breathing. Oftentimes, these diseases occur as a result of altered immune response in the lung. The aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor, acts as a regulator of mucosal barrier function and may influence immune responsiveness in lung diseases through changes in gene expression, cell-cell adhesion, mucin production, and cytokine expression. Of these cytokines, interleukin 22 (IL-22) signaling appears to be involved in lung inflammation and fibrosis, and both endogenous and exogenous AhR agonists promote IL-22 expression. Therefore, this chapter discusses the role of the AhR pathway and IL-22 signaling in lung diseases such as chronic obstructive pulmonary disorder, idiopathic fibrosis, Sarcoidosis, acute respiratory distress syndrome, and silicosis. Finally, we address the therapeutic potential of targeting the AhR—IL-22 axis in regulating immunity, inflammation, and tissue homeostasis in lung diseases.
KW - Acute Respiratory Distress Syndrome
KW - Aryl Hydrocarbon Receptor
KW - Chronic Obstructive Pulmonary Disease
KW - Chronic Obstructive Pulmonary Disease Patient
KW - Idiopathic Pulmonary Fibrosis
UR - http://www.scopus.com/inward/record.url?scp=84871661029&partnerID=8YFLogxK
U2 - 10.1007/978-1-61779-812-2_13
DO - 10.1007/978-1-61779-812-2_13
M3 - Chapter
AN - SCOPUS:84871661029
T3 - Molecular and Integrative Toxicology
SP - 313
EP - 343
BT - Molecular and Integrative Toxicology
PB - Springer Science+Business Media B.V.
ER -